Gross Profit Trends Compared: Perrigo Company plc vs Ligand Pharmaceuticals Incorporated

Perrigo vs Ligand: A Decade of Gross Profit Trends

__timestampLigand Pharmaceuticals IncorporatedPerrigo Company plc
Wednesday, January 1, 2014554020001447700000
Thursday, January 1, 2015661070001712400000
Friday, January 1, 20161034020002051800000
Sunday, January 1, 20171357360001979500000
Monday, January 1, 20182451160001831500000
Tuesday, January 1, 20191089350001773300000
Wednesday, January 1, 20201560000001815200000
Friday, January 1, 20212149570001416200000
Saturday, January 1, 20221434180001455400000
Sunday, January 1, 2023962650001680400000
Loading chart...

Unlocking the unknown

Gross Profit Trends: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, understanding financial trends is crucial. This analysis compares the gross profit trajectories of Perrigo Company plc and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Perrigo, a global leader in over-the-counter health products, consistently outperformed Ligand, a company known for its innovative drug discovery technologies. Over the decade, Perrigo's gross profit averaged around $1.7 billion, peaking in 2016 with a 20% increase from 2014. In contrast, Ligand's gross profit, while significantly lower, showed a remarkable growth of 340% from 2014 to 2018, highlighting its dynamic expansion strategy. However, both companies faced fluctuations, with Perrigo experiencing a dip in 2021 and Ligand peaking in 2018 before a decline. These trends underscore the volatile yet promising nature of the pharmaceutical industry, where strategic innovation and market adaptation are key to financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025